Advertisement

Receptors, Neuroleptics and Dopamine Concentrations in Schizophrenia — Postmortem Studies of Human Brain Tissue

  • G. P. Reynolds

Abstract

There is little doubt that biochemical investigation of human postmortem brain tissue has made a substantial contribution to the understanding and treatment of disease. It was as a direct result of the observation of a dopamine deficit in the corpus striatum of Parkinson’s disease patients that L-dopa was introduced and found to be so successful (Birkmayer and Hornykiewicz 1962). Unfortunately, such a valuable advance has yet to be made in other fields of neuropsychiatry, although recently some potentially important findings have been made towards our understanding of schizophrenia and the mechanisms of antipsychotic drugs.

Keywords

Dopamine Receptor Temporal Lobe Epilepsy Human Brain Tissue Dopamine Concentration Neuroleptic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bennett JP, Enna SJ, Bylund DB, Gillin JC, Wyatt RJ, Snyder SH (1979) Neurotransmitter receptors in frontal cortex of schizophrenics. Arch Gen Psychiatry 36: 927–934PubMedGoogle Scholar
  2. Bird ED, Spokes EGS, Iversen LL (1979) Increased dopamine concentration in limbic areas of brain from patients dying with schizophrenia. Brain 102: 347–360PubMedCrossRefGoogle Scholar
  3. Birkmayer W, Horaykiewicz O (1962) Der L-3,4-Dioxyphenylalanin ( L-Dopa)-Effekt beim Parkinson-Syndrom des Menschen. Arch Psychiatr Nervenkr 203: 560–574CrossRefGoogle Scholar
  4. Borison RL, Fields JZ, Diamond RI (1981) Site specific blockade of dopamine receptors by neuroleptic agents in human brain. Neuropharmacology 20: 1321–1322PubMedGoogle Scholar
  5. Clow A, Theodorou A, Jenner P, Marsden CD (1980) Changes in rat striatal dopamine turnover and receptor activity during one year’s neuroleptic administration. Eur J Pharmacol 63: 135–144PubMedCrossRefGoogle Scholar
  6. Crow TJ, Owen F, Cross AJ, Ferner N, Johnstone EC, McCreadie RM, Owens DGC, Poulter M (1981) Neurotransmitter enzymes and receptors in post mortem brain in schizophrenia: evidence that an increase in D2 dopamine receptors is associated with the type I syndrome. In: Riederer P, Usdin E (eds) Transmitter biochemistry of human brain tissue. Macmillan, London, pp 85–96Google Scholar
  7. Flor-Henry P (1969) Psychosis and temporal lobe epilepsy: a controlled investigation. Epilepsia 10: 363–395PubMedCrossRefGoogle Scholar
  8. Gruzelier JH (1981) Cerebral laterality and psychopathology: fact and fiction. Psychological Med 11: 219–227CrossRefGoogle Scholar
  9. Hornykiewicz O (1982) Brain catecholamines in schizophrenia — a good case for noradrenaline. Nature 299: 484–486PubMedCrossRefGoogle Scholar
  10. Mackay AVP, Bird ED, Spokes EL, Rossor M, Iversen LL, Creese I, Snyder SH (1980) Dopamine receptors and schizophrenia: drug effect or illness? Lancet 11: 223–225Google Scholar
  11. Mackay AVP, Iversen LL, Rossor M, Spokes E, Bird E, Arregui A, Creese I, Snyder SH (1982) Increased brain dopamine and dopamine receptors in schizophrenia. Arch Gen Psychiatry 39: 991–997PubMedGoogle Scholar
  12. Owen F, Crow TJ, Poulter M, Cross AJ, Longden A, Riley GJ (1978) Increased dopamine-receptor sensitivity in schizophrenia. Lancet 11: 915–916Google Scholar
  13. Peroutka SJ, Lebowitz RM, Snyder SH (1981) Two distinct serotonin receptors with different physiological functions. Science 212: 827–829PubMedCrossRefGoogle Scholar
  14. Reynolds GP (1983a) (3H)-Ketanserin binding to 5-HT2 receptors in human brain. Br J Pharmacol 78:273 pGoogle Scholar
  15. Reynolds GP (1983b) Increased concentrations and lateral asymmetry of amygdala dopamine in schizophrenia. Nature 305: 527–529PubMedCrossRefGoogle Scholar
  16. Reynolds GP, Riederer P, Jellinger K, Gabriel E (1981) Dopamine receptors and schizophrenia: the neuroleptic drug problem. Neuropharmacology 20: 1319–1320PubMedGoogle Scholar
  17. Reynolds GP, Cowey L, Rossor M, Iversen LL (1982a) Thioridazine is not specific for limbic dopamine receptors. Lancet 11: 499–500CrossRefGoogle Scholar
  18. Reynolds GP, Riederer P, Jellinger K, Gabriel E (1982b) Effects of neuroleptic treatment and disease state on dopamine receptors in post-mortem schizophrenic brain. Neuroscience 7: S177Google Scholar
  19. Reynolds GP, Rossor MN, Iversen LL (1983) Preliminary studies of human cortical 5-HT2 receptors and their involvement in schizophrenia and neuroleptic drug action. J Neural Trans [Suppl] 18: 273–277Google Scholar
  20. Snyder S, Greenberg D, Yamamura HI (1974) Antischizophrenic drugs and brain cholinergic receptors. Arch Gen Psychiatry 31: 58–61PubMedGoogle Scholar
  21. Stevens JR (1979) Schizophrenia and dopamine regulation in the mesolimbic system. Trends Neurosci 2: 102–105CrossRefGoogle Scholar
  22. Trulson ME, Jacobs BL (1979) Long-term amphetamine treatment decreases brain serotonin metabolism: implications for theories of schizophrenia. Science 205: 1295–1297PubMedCrossRefGoogle Scholar
  23. Whitaker PM, Crow TJ, Ferrier IN (1981) Tritiated LSD binding in frontal cortex in schizophrenia. Arch Gen Psychiatry 38: 278–280PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1985

Authors and Affiliations

  • G. P. Reynolds

There are no affiliations available

Personalised recommendations